Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Eradicating H. pylori may cut risk of gastric cancer

Key clinical point: Eradication of Helicobacter pylori infection was associated with a significant reduction in risk of subsequent distal gastric adenocarcinoma.

Major finding: The standardized hazard ratio for risk of gastric cancer was 0.24 (95% confidence interval, 0.15-0.41; P less than .001) when comparing patients with and without eradicated H. pylori infections.

Study details: Retrospective cohort study of 371,813 patients with H. pylori infection from the U.S. Veterans Health Administration.

Disclosures: Dr. Kumar is supported by a training grant from the National Institutes of Health. She disclosed travel support from Boston Scientific and Olympus. Her coinvestigators disclosed ties to Takeda, Novartis, Janssen, Gilead, Bayer, and several other companies.

Citation:

Kumar S et al. Gastroenterology. 2019 Oct 1. doi: 10.1053/j.gastro.2019.10.019.